Search

Your search keyword '"Barbier, Emilie"' showing total 23 results
Start Over Author "Barbier, Emilie"
23 results on '"Barbier, Emilie"'

1. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

Author

Aparicio, Thomas, Bouché, Olivier, Etienne, Pierre-Luc, Barbier, Emilie, Mineur, Laurent, Desgrippes, Romain, Guérin-Meyer, Véronique, Hocine, Fayçal, Martin, Jean, Le Brun-Ly, Valérie, Cretin, Jacques, Desramé, Jérôme, Rinaldi, Yves, Cany, Laurent, Falandry, Claire, Lefevre, Leila Bengrine, Marous, Miguelle, Terrebonne, Eric, Mosser, Laurent, Turpin, Justine, Turpin, Anthony, Bauguion, Lucille, Reichling, Cynthia, Van den Eynde, Marc, Carola, Elisabeth, and Hiret, Sandrine

Published
2023
Full Text
View/download PDF

2. What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort

Author

Bacci, Manon, Quero, Laurent, Barbier, Emilie, Parrot, Laurène, Juguet, Frédéric, Pommier, Pascal, Bazire, Louis, Etienney, Isabelle, Baba-Hamed, Nabil, Spindler, Lucas, François, Eric, Ronchin, Philippe, Campo, Eleonor Rivin Del, Lemanski, Claire, Lièvre, Astrid, Siproudhis, Laurent, Abramowitz, Laurent, Lepage, Côme, and Vendrely, Véronique

Published
2021
Full Text
View/download PDF

3. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Author

Taïeb, Julien, André, Thierry, El Hajbi, Farid, Barbier, Emilie, Toullec, Clémence, Kim, Stefano, Bouche, Olivier, Di Fiore, Frederic, Chauvenet, Marion, Perrier, Hervé, Evesque, Ludovic, Laurent-Puig, Pierre, Emile, Jean-François, Bez, Jérémie, Lepage, Côme, and Tougeron, David

Published
2021
Full Text
View/download PDF

4. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study

Author

Manfredi, Sylvain, Turpin, Anthony, Malka, David, Barbier, Emilie, Laurent-Puig, Pierre, Zaanan, Aziz, Dahan, Laeticia, Lièvre, Astrid, Phelip, Jean-Marc, Michel, Pierre, Hautefeuille, Vincent, Legoux, Jean-Louis, Lepage, Côme, Tougeron, David, and Aparicio, Thomas

Published
2020
Full Text
View/download PDF

5. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study

Author

Randrian, Violaine, Adenis, Antoine, Desrame, Jérôme, Barbier, Emilie, Di Fiore, Frédéric, Lièvre, Astrid, Dahan, Laetitia, Laurent-Puig, Pierre, Mineur, Laurent, Breysacher, Gilles, Roquin, Guillaume, Louafi, Samy, Lopez, Anthony, Louvet, Christophe, Borg, Christophe, Metges, Jean Philippe, Faroux, Roger, Gaba, Lila, Manfredi, Sylvain, and Tougeron, David

Published
2020
Full Text
View/download PDF

6. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction:A Network Meta-Analysis

Author

Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, Vey, Johannes A., Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, and Vey, Johannes A.

Abstract

Importance: The prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone. Objective: To assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes. Data Sources:Literature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023. Study Selection: Two blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria. Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach. Main Outcomes and Measures: Overall and disease-free survival, postoperative morbidity, and mortality. Results:The analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperativ

Published
2024

7. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study

Author

Walter, Thomas, Lepage, Come, Coriat, Romain, Barbier, Emilie, Cadiot, Guillaume, Caroli-Bosc, Francois-Xavier, Aparicio, Thomas, Bouhier-Leporrier, Karine, Hentic-Dhome, Olivia, Gay, Frédérique, Dupont-Gossart, Anne-Claire, Duluc, Muriel, Lepere, Céline, Lecomte, Thierry, Smith, Denis, Petorin, Caroline, Di-Fiore, Frédéric, Ghiringhelli, Francois, Legoux, Jean-Louis, Guimbaud, Rosine, Baudin, Eric, Lombard-Bohas, Catherine, and de Baère, Thierry

Published
2019
Full Text
View/download PDF

8. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)

Author

Vendrely, Véronique, Lemanski, Claire, Gnep, Khemara, Barbier, Emilie, Hajbi, Farid El, Lledo, Gerard, Dahan, Laëtitia, Terrebonne, Eric, Manfredi, Sylvain, Mirabel, Xavier, Mammar, Vincent, Cowen, Didier, Lepage, Come, and Aparicio, Thomas

Published
2019
Full Text
View/download PDF

9. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

Author

Jouve, Jean-Louis, Lecomte, Thierry, Bouché, Olivier, Barbier, Emilie, Khemissa Akouz, Faiza, Riachi, Ghassan, Nguyen Khac, Eric, Ollivier-Hourmand, Isabelle, Debette-Gratien, Maryline, Faroux, Roger, Villing, Anne-Laure, Vergniol, Julien, Ramee, Jean-François, Bronowicki, Jean-Pierre, Seitz, Jean-François, Legoux, Jean-Louis, Denis, Jacques, Manfredi, Sylvain, and Phelip, Jean-Marc

Published
2019
Full Text
View/download PDF

10. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

11. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, Aparicio, Thomas, Bouché, Olivier, Etienne, Pierre-Luc, Barbier, Emilie, Mineur, Laurent, Desgrippes, Romain, Guérin-Meyer, Véronique, Hocine, Fayçal, Martin, Jean, Le Brun-Ly, Valérie, Cretin, Jacques, Desramé, Jérôme, Rinaldi, Yves, Cany, Laurent, Falandry, Claire, Lefevre, Leila Bengrine, Marous, Miguelle, Terrebonne, Eric, Mosser, Laurent, Turpin, Justine, Turpin, Anthony, Bauguion, Lucille, Reichling, Cynthia, Van den Eynde, Marc, Carola, Elisabeth, Hiret, Sandrine, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, Aparicio, Thomas, Bouché, Olivier, Etienne, Pierre-Luc, Barbier, Emilie, Mineur, Laurent, Desgrippes, Romain, Guérin-Meyer, Véronique, Hocine, Fayçal, Martin, Jean, Le Brun-Ly, Valérie, Cretin, Jacques, Desramé, Jérôme, Rinaldi, Yves, Cany, Laurent, Falandry, Claire, Lefevre, Leila Bengrine, Marous, Miguelle, Terrebonne, Eric, Mosser, Laurent, Turpin, Justine, Turpin, Anthony, Bauguion, Lucille, Reichling, Cynthia, Van den Eynde, Marc, Carola, Elisabeth, and Hiret, Sandrine

Abstract

Background: Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection, but this improvement was not demonstrated in older patients. Methods: The purpose of ADAGE-PRODIGE 34, randomized open phase III trial is to compare in patients over 70 years oxaliplatin plus fluoropyrimidine with fluoropyrimidine alone in fit patients (Group 1) and fluoropyrimidine with observation in frail patients (Group 2) after resection of stage III colon adenocarcinoma. We report a preliminary tolerance analysis on 50% of the first patients enrolled. Results: The analysis was conducted on 491 patients (378 in Group 1 and 113 in Group 2). Patients in Group 2 were older and showed more frailty criteria than those in Group 1. Cumulative grade 3-5 toxicities were more frequent in patients treated with oxaliplatin in Group 1 or with fluoropyrimidine in Group 2 than in patients treated with fluoropyrimidine in Group 1. At least one course was deferred in more than half of the patients in all groups. Early treatment cessation was more frequent in Group 2. Conclusion: No safety concerns were raised for the continuation of accrual. The frailty criteria distribution suggests that the investigator's evaluation for group allocation was accurate.

Published
2022

12. Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.

Author

Manfredi, Sylvain, Dior, Marie, Bouche, Olivier, Barbier, Emilie, Hautefeuille, Vincent, Guillet, Marielle, Turpin, Justine, Bourgeois, Vincent, Helene, Dall Osto, Desgrippes, Romain, Audemar, Franck, Molin, Yann, Locher, Christophe, Chatellier, Thierry, Lecomte, Thierry, Baize, Nathalie, Lecaille, Cedric, Spaeth, Dominique, Goujon, Gael, and Lepage, Come

Subjects
ESOPHAGOGASTRIC junction, PROGRESSION-free survival, CANCER chemotherapy, COMBINATION drug therapy, STOMACH cancer
Abstract

Background: Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junction cancers. We aimed to describe chemotherapy practices, tolerance, and efficacy overall survival (OS) and Progression free survival (PFS) in a prospective French cohort. Methods: Patients starting palliative chemotherapy were prospectively enrolled in 49 French centres. The primary objective was to report and describe patients' characteristics and treatment strategies. Secondary objectives were OS, PFS, objective response rate, adverse events rate, performance status deterioration during the chemotherapy. Results: A total of 182 patients were included; 179 were analysed. Most patients received platinium‐based chemotherapy as the first treatment and FOLFIRI as second; 62.0% of patients received a second line, and 32.4% a third line. More than two thirds of Her2‐positive patients were first treated with trastuzumab. The FOLFIRI regimen was the most frequently used second‐line therapy. Median OS was 13.3 months, similar whatever the chemotherapy or combinations used in the first line. One‐ and 2‐year OS increased with the number of chemotherapy lines received, from respectively 24.7% and 5.7% (1 line), to 46.9% and 12.4% (2 lines) and 88.1% and 29.9% (3 or more lines) (p < 0.0001). Conclusion: Our study showed that treatment strategies in France are based on a succession of doublets, making it possible to offer a second and third line of treatment more often. This treatment strategy must be taken into account for future trials with immunotherapy combinations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma

Author

Giraud, Nicolas, primary, Saut, Olivier, additional, Aparicio, Thomas, additional, Ronchin, Philippe, additional, Bazire, Louis-Arnaud, additional, Barbier, Emilie, additional, Lemanski, Claire, additional, Mirabel, Xavier, additional, Etienne, Pierre-Luc, additional, Lièvre, Astrid, additional, Cacheux, Wulfran, additional, Darut-Jouve, Ariane, additional, De la Fouchardière, Christelle, additional, Hocquelet, Arnaud, additional, Trillaud, Hervé, additional, Charleux, Thomas, additional, Breysacher, Gilles, additional, Argo-Leignel, Delphine, additional, Tessier, Alexandre, additional, Magné, Nicolas, additional, Ben Abdelghani, Meher, additional, Lepage, Côme, additional, and Vendrely, Véronique, additional

Published
2021
Full Text
View/download PDF

14. Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial.

Author

Karoui, Medhi, primary, Gallois, Claire, additional, Piessen, Guillaume, additional, Legoux, Jean-Louis, additional, Barbier, Emilie, additional, De Chaisemartin, Cecile, additional, Lecaille, Cedric, additional, Bouché, Olivier, additional, Ammarguellat, Hanifa, additional, Brunetti, Francesco, additional, Prudhomme, Michel, additional, Regimbeau, Jean-Marc, additional, Glehen, Olivier, additional, Lièvre, Astrid, additional, Portier, Guillaume, additional, Hartwig, Johannes, additional, Goujon, Gael, additional, Romain, Benoît, additional, Lepage, Come, additional, and Taieb, Julien, additional

Published
2020
Full Text
View/download PDF

15. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.

Author

Phelip, Jean Marc, Desrame, Jérôme, Edeline, Julien, Barbier, Emilie, Terrebonne, Eric, Michel, Pierre, Perrier, Hervé, Dahan, Laetitia, Bourgeois, Vincent, Akouz, Faiza Khemissa, Soularue, Emilie, Ly, Valérie Lebrun, Molin, Yann, Lecomte, Thierry, Ghiringhelli, François, Coriat, Romain, Louafi, Samy, Neuzillet, Cindy, Manfredi, Sylvain, and Malka, David

Published
2022
Full Text
View/download PDF

16. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.

Author

Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf-Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, and Nilsson, Magnus

Published
2024
Full Text
View/download PDF

17. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial

Author

Guiu, Boris, primary, Chevallier, Patrick, additional, Assenat, Eric, additional, Barbier, Emilie, additional, Merle, Philippe, additional, Bouvier, Antoine, additional, Dumortier, Jérôme, additional, Nguyen-Khac, Eric, additional, Gugenheim, Jean, additional, Rode, Agnès, additional, Oberti, Frédéric, additional, Valette, Pierre-Jean, additional, Yzet, Thierry, additional, Chevallier, Olivier, additional, Barbare, Jean-Claude, additional, Latournerie, Marianne, additional, and Boulin, Mathieu, additional

Published
2019
Full Text
View/download PDF

18. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Author

Dohan, Anthony, primary, Gallix, Benoit, additional, Guiu, Boris, additional, Le Malicot, Karine, additional, Reinhold, Caroline, additional, Soyer, Philippe, additional, Bennouna, Jaafar, additional, Ghiringhelli, Francois, additional, Barbier, Emilie, additional, Boige, Valérie, additional, Taieb, Julien, additional, Bouché, Olivier, additional, François, Eric, additional, Phelip, Jean-Marc, additional, Borel, Christian, additional, Faroux, Roger, additional, Seitz, Jean-Francois, additional, Jacquot, Stéphane, additional, Ben Abdelghani, Meher, additional, Khemissa-Akouz, Faiza, additional, Genet, Dominique, additional, Jouve, Jean Louis, additional, Rinaldi, Yves, additional, Desseigne, Françoise, additional, Texereau, Patrick, additional, Suc, Etienne, additional, Lepage, Come, additional, Aparicio, Thomas, additional, and Hoeffel, Christine, additional

Published
2019
Full Text
View/download PDF

19. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial.

Author

Karoui, Mehdi, Gallois, Claire, Piessen, Guillaume, Legoux, Jean‐Louis, Barbier, Emilie, De Chaisemartin, Cecile, Lecaille, Cedric, Bouche, Olivier, Ammarguellat, Hanifa, Brunetti, Francesco, Prudhomme, Michel, Regimbeau, Jean‐Marc, Glehen, Olivier, Lievre, Astrid, Portier, Guillaume, Hartwig, Johannes, Goujon, Gael, Romain, Benoit, Lepage, Come, and Taieb, Julien

Subjects
NEOADJUVANT chemotherapy, COLON cancer, PROGNOSIS, COMPUTED tomography, OVERALL survival
Abstract

Aim: Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3‐year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method: PRODIGE 22 was a randomized multicentre phase II trial in high‐risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild‐type RAS patients, a third arm testing perioperative FOLFOX‐cetuximab was added. The primary endpoint was the tumour regression grade. Secondary endpoints were 3‐year overall survival (OS), disease‐free survival (DFS), recurrence‐free survival (RFS) and time to recurrence (TTR). Results: Overall, 120 patients were enrolled. At interim analysis, the FOLFOX‐cetuximab arm was stopped for futility. The remaining 104 patients represented our intention‐to‐treat population. In the perioperative group, 96% received the scheduled four neoadjuvant cycles and all but one had adjuvant FOLFOX for eight cycles. In the control arm, 38 (73%) patients received adjuvant FOLFOX. The median follow‐up was 54.3 months. Three‐year OS was 90.4% in both arms [hazard ratio (HR) = 0.85], 3‐year DFS, RFS and TTR were, respectively, 76.8% and 69.2% (HR=0.94), 73% and 69.2% (HR = 0.86) and 82% and 72% (HR = 0.67) in the perioperative and control arms, respectively. Forest plots did not show any subgroup with significant difference for survival outcomes. No benefit from adding cetuximab was observed. Conclusion: Perioperative FOLFOX has no detrimental effect on long‐term oncological outcomes and may be an option for some patients with locally advanced CC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study

Author

Phelip, Jean-Marc, primary, Edeline, Julien, additional, Blanc, Jean-Frédéric, additional, Barbier, Emilie, additional, Michel, Pierre, additional, Bourgeois, Vincent, additional, Neuzillet, Cindy, additional, Malka, David, additional, Manfredi, Sylvain, additional, and Desrame, Jérôme, additional

Published
2019
Full Text
View/download PDF

21. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Aparicio, Thomas, primary, Ducreux, Michel, additional, Faroux, Roger, additional, Barbier, Emilie, additional, Manfredi, Sylvain, additional, Lecomte, Thierry, additional, Etienne, Pierre-Luc, additional, Bedenne, Laurent, additional, Bennouna, Jaafar, additional, Phelip, Jean-Marc, additional, François, Eric, additional, Michel, Pierre, additional, Legoux, Jean-Louis, additional, Gasmi, Mohamed, additional, Breysacher, Gilles, additional, Rougier, Philippe, additional, De Gramont, Aimery, additional, Lepage, Come, additional, Bouché, Olivier, additional, Seitz, Jean-François, additional, Adenis, A., additional, Alessio, A., additional, Aouakli, A., additional, Azzedine, A., additional, Bedjaoui, A., additional, Bidault, A., additional, Blanchi, A., additional, Botton, A., additional, Cadier-Lagnes, A., additional, Fatisse, A., additional, Gagnaire, A., additional, Gilbert, A., additional, Gueye, A., additional, Hollebecque, A., additional, Lemaire, A., additional, Mahamat, A., additional, Marre, A., additional, Patenotte, A., additional, Rotenberg, A., additional, Roussel, A., additional, Thirot-Bidault, A., additional, Votte, A., additional, Weber, A., additional, Zaanan, A., additional, Dupont-Gossart, A.C., additional, Villing, A.L., additional, Queuniet, A.M., additional, Coudert, B., additional, Denis, B., additional, Garcia, B., additional, Lafforgue, B., additional, Landi, B., additional, Leduc, B., additional, Linot, B., additional, Paillot, B., additional, Rhein, B., additional, Winkfield, B., additional, Barberis, C., additional, Becht, C., additional, Belletier, C., additional, Berger, C., additional, Bineau, C., additional, Borel, C., additional, Brezault, C., additional, Buffet, C., additional, Cornila, C., additional, Couffon, C., additional, De La Fouchardière, C., additional, Giraud, C., additional, Lecaille, C., additional, Lepere, C., additional, Lobry, C., additional, Locher, C., additional, Lombard-Bohas, C., additional, Paoletti, C., additional, Platini, C., additional, Rebischung, C., additional, Sarda, C., additional, Vilain, C., additional, Briac-Levaché, C., additional, Auby, D., additional, Baudet-Klepping, D., additional, Bechade, D., additional, Besson, D., additional, Cleau, D., additional, Festin, D., additional, Gargot, D., additional, Genet, D., additional, Goldfain, D., additional, Luet, D., additional, Malka, D., additional, Peré-Vergé, D., additional, Pillon, D., additional, Sevin-Robiche, D., additional, Smith, D., additional, Soubrane, D., additional, Tougeron, D., additional, Zylberait, D., additional, Carola, E., additional, Cuillerier, E., additional, Dorval Danquechin, E., additional, Echinard, E., additional, Janssen, E., additional, Maillard, E., additional, Mitry, E., additional, Norguet-Monnereau, E., additional, Suc, E., additional, Terrebonne, E., additional, Zrihen, E., additional, Pariente, E.A., additional, Almaric, F., additional, Audemar, F., additional, Bonnetain, F., additional, Desseigne, F., additional, Dewaele, F., additional, Di Fiore, F., additional, Ghiringhelli, F., additional, Husseini, F., additional, Khemissa, F., additional, Kikolski, F., additional, Morvan, F., additional, Petit-Laurent, F., additional, Riot, F., additional, Subtil, F., additional, Zerouala-Boussaha, F., additional, Caroli-Bosc, F.X., additional, Boilleau-Jolimoy, G., additional, Bordes, G., additional, Cavaglione, G., additional, Coulanjon, G., additional, Deplanque, G., additional, Gatineau-Saillant, G., additional, Goujon, G., additional, Medinger, G., additional, Roquin, G., additional, Brixi-Benmansour, H., additional, Castanie, H., additional, Lacroix, H., additional, Maechel, H., additional, Perrier, H., additional, Salloum, H., additional, Senellart, H., additional, Baumgaertner, I., additional, Cumin, I., additional, Graber, I., additional, Trouilloud, I., additional, Boutin, J., additional, Butel, J., additional, Charneau, J., additional, Cretin, J., additional, Dauba, J., additional, Deguiral, J., additional, Egreteau, J., additional, Ezenfis, J., additional, Forestier, J., additional, Goineau, J., additional, Lacourt, J., additional, Lafon, J., additional, Martin, J., additional, Meunier, J., additional, Moreau, J., additional, Provencal, J., additional, Taieb, J., additional, Thaury, J., additional, Tuaillon, J., additional, Vergniol, J., additional, Villand, J., additional, Vincent, J., additional, Volet, J., additional, Bachet, J.B., additional, Barbare, J.C., additional, Souquet, J.C., additional, Grangé, J.D., additional, Dor, J.F., additional, Paitel, J.F., additional, Jouve, J.L., additional, Raoul, J.L., additional, Cheula, J.M., additional, Gornet, J.M., additional, Sabate, J.M., additional, Vantelon, J.M., additional, Vaillant, J.N., additional, Aucouturier, J.P., additional, Barbieux, J.P., additional, Herr, J.P., additional, Lafargue, J.P., additional, Lagasse, J.P., additional, Latrive, J.P., additional, Plachot, J.P., additional, Ramain, J.P., additional, Robin, J.P., additional, Spano, J.P., additional, Douillard, J.Y., additional, Beerblock, K., additional, Bouhier-Leporrier, K., additional, Slimane Fawzi, K., additional, Cany, L., additional, Chone, L., additional, Dahan, L., additional, Gasnault, L., additional, Rob, L., additional, Stefani, L., additional, Wander, L., additional, Baconnier, M., additional, Ben Abdelghani, M., additional, Benchalal, M., additional, Blasquez, M., additional, Carreiro, M., additional, Charbit, M., additional, Combe, M., additional, Duluc, M., additional, Fayolle, M., additional, Gignoux, M., additional, Giovannini, M., additional, Glikmanas, M., additional, Mabro, M., additional, Mignot, M., additional, Mornet, M., additional, Mousseau, M., additional, Mozer, M., additional, Pauwels, M., additional, Pelletier, M., additional, Porneuf, M., additional, Ramdani, M., additional, Schnee, M., additional, Tissot, M., additional, Zawadi, M., additional, Clavero-Fabri, M.C., additional, Gouttebel, M.C., additional, Kaminsky, M.C., additional, Galais, M.P., additional, Abdelli, N., additional, Barrière, N., additional, Bouaria, N., additional, Bouarioua, N., additional, Delas, N., additional, Gérardin, N., additional, Hess-Laurens, N., additional, Stremsdoerfer, N., additional, Berthelet, O., additional, Boulat, O., additional, Capitain, O., additional, Favre, O., additional, Amoyal, P., additional, Bergerault, P., additional, Burtin, P., additional, Cassan, P., additional, Chatrenet, P., additional, Chiappa, P., additional, Claudé, P., additional, Couzigou, P., additional, Feydy, P., additional, Follana, P., additional, Geoffroy, P., additional, Godeau, P., additional, Hammel, P., additional, Laplaige, P., additional, Lehair, P., additional, Martin, P., additional, Novello, P., additional, Pantioni, P., additional, Pienkowski, P., additional, Pouderoux, P., additional, Prost, P., additional, Ruszniewski, P., additional, Souillac, P., additional, Texereau, P., additional, Thévenet, P., additional, Haineaux, P.A., additional, Benoit, R., additional, Coriat, R., additional, Lamy, R., additional, Mackiewicz, R., additional, Beorchia, S., additional, Chaussade, S., additional, Hiret, S., additional, Jacquot, S., additional, Lavau Denes, S., additional, Montembault, S., additional, Nahon, S., additional, Nasca, S., additional, Nguyen, S., additional, Oddou-Lagraniere, S., additional, Pesque-Penaud, S., additional, Fratte, S.P., additional, Chatellier, T., additional, Mansourbakht, T., additional, Morin, T., additional, Walter, T., additional, Boige, V., additional, Bourgeois, V., additional, Derias, V., additional, Guérin-Meyer, V., additional, Hautefeuille, V., additional, Jestin Le Tallec, V., additional, Lorgis, V., additional, Quentin, V., additional, Sebbagh, V., additional, Veuillez, V., additional, Adhoute, X., additional, Coulaud, X., additional, Becouarn, Y., additional, Coscas, Y., additional, Courouble, Y., additional, Le Bricquir, Y., additional, Molin, Y., additional, Rinaldi, Y., additional, Lam, Y.H., additional, and Ladhib, Z., additional

Published
2018
Full Text
View/download PDF

22. Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

Author

Taieb, Julien, primary, Rinaldi, Yves, additional, Pointet, Anne-Laure, additional, Barbier, Emilie, additional, Khemissa, Faiza, additional, Gratet, Alain, additional, Miglianico, Laurent, additional, Laharie-Mineur, Hortense, additional, Bouhier-Leporrier, Karine, additional, Ghiringhelli, François, additional, Thirot Bidault, Anne, additional, Texereau, Patrick, additional, Coriat, Romain, additional, Terrebonne, Eric, additional, Gouttebel, Marie-Claude, additional, Malka, David, additional, Lepage, Come, additional, and Bachet, Jean-Baptiste, additional

Published
2018
Full Text
View/download PDF

23. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Author

Dohan, Anthony, Gallix, Benoit, Guiu, Boris, Le Malicot, Karine, Reinhold, Caroline, Soyer, Philippe, Bennouna, Jaafar, Ghiringhelli, Francois, Barbier, Emilie, Boige, Valérie, Taieb, Julien, Bouché, Olivier, François, Eric, Phelip, Jean-Marc, Borel, Christian, Faroux, Roger, Seitz, Jean-Francois, Jacquot, Stéphane, Ben Abdelghani, Meher, and Khemissa-Akouz, Faiza

Subjects
LIVER metastasis, COLORECTAL cancer
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results